Premium
Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double‐blind placebo‐controlled study in active Crohn’s disease
Author(s) -
Steed H.,
Macfarlane G. T.,
Blackett K. L.,
Bahrami B.,
Reynolds N.,
Walsh S. V.,
Cummings J. H.,
Macfarlane S.
Publication year - 2010
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2010.04417.x
Subject(s) - crohn's disease , medicine , immune system , gastroenterology , placebo , disease , bifidobacterium , immunology , synbiotics , bifidobacterium longum , clinical trial , probiotic , pathology , lactobacillus , biology , bacteria , alternative medicine , genetics
Aliment Pharmacol Ther 2010; 32: 872–883 Summary Background Crohn’s disease is an inflammatory illness in which the immune response against gut microorganisms is believed to drive an abnormal immune response. Consequently, modification of mucosal bacterial communities, and the immune effects they elicit, might be used to modify the disease state. Aim To investigate the effects of synbiotic consumption on disease processes in patients with Crohn's disease. Methods A randomized, double‐blind placebo‐controlled trial was conducted involving 35 patients with active Crohn's disease, using a synbiotic comprising Bifidobacterium longum and Synergy 1. Clinical status was scored and rectal biopsies were collected at the start, and at 3‐ and 6‐month intervals. Transcription levels of immune markers and mucosal bacterial 16S rRNA gene copy numbers were quantified using real‐time PCR. Results Significant improvements in clinical outcomes occurred with synbiotic consumption, with reductions in both Crohn's disease activity indices ( P = 0.020) and histological scores ( P = 0.018). The synbiotic had little effect on mucosal IL‐18, INF‐γ and IL‐1β; however, significant reductions occurred in TNF‐α expression in synbiotic patients at 3 months ( P = 0.041), although not at 6 months. Mucosal bifidobacteria proliferated in synbiotic patients. Conclusion Synbiotic consumption was effective in improving clinical symptoms in patients with active Crohn's disease.